

# UCB

## Inspired by patients. Driven by science.

Dale Starkie and Amy Sawtell


Research Scientists, UCB

Industrial Biotechnology and Bioenergy  
Careers Fair, 12<sup>th</sup> April 2017




Carolin, living with  
epilepsy and axial  
spondyloarthritis

# UCB: Scientific Heritage



# UCB's Patient Value Strategy



**We deliver highly differentiated solutions to specific populations, striving for a unique experience for each patient.**

# UCB: A Global Player

Presence in 38 countries  
completed by a robust network of partners



2

## RESEARCH CENTERS

- Braine-l'Alleud (Belgium)
- Slough (U.K.)

5


## DEVELOPMENT HUBS

- RTP North Carolina (U.S.)
- Monheim (Germany)
- Brussels (Belgium)
- Tokyo (Japan)
- Shanghai (China)

4

## MANUFACTURING FACILITIES

- Braine-l'Alleud (Belgium)
- Zuhai (China)
- Saitama (Japan)
- Bulle (Switzerland)



# UCB Antibody Technology

## Celltech Heritage

### Cloning and expression of antibody genes

#### The Boss Patent

*“Chimeric immunoglobulin molecules are produced by cloning cDNA sequences encoding human constant regions together with non-human variable regions..”*

### The synthesis and *in vivo* assembly of functional antibodies in yeast

**Clive R. Wood, Michael A. Boss, John H. Kenten,  
Jane E. Calvert\*, Nicola A. Roberts†  
& J. Spencer Emtage**

Celltech Ltd, 244-250 Bath Road, Slough, Berkshire SL1 4DY, UK  
† Department of Biochemistry, University of Oxford,  
South Parks Road, Oxford OX1 3QU, UK

1985 Nature 314:446-449

### Humanisation of antibody sequences The Adair Patent

*“Humanised antibody molecules prepared according to this alternative approach, i.e. CDR-grafted humanised antibody molecules... less likely to give rise to a HAMA response .. in view of the much lower proportion of non-human amino acid sequence which they contain”*

United States Patent [19]

Adair et al.

US005859205A

5,859,205

Jan. 12, 1999

[54] HUMANISED ANTIBODIES

[75] Inventors: John Robert Adair, High Wycombe;

Diljeet Singh AthWal, London; John

Spencer Emtage, Marlow, all of United

Kingdom

[73] Assignee: Celltech Limited, Berkshire, United

Kingdom




# UCB utilises cutting edge technologies in drug discovery

| Core antibody discovery robotics platform




# We aim to bring our medicines to specific subpopulations of patients



# 10 NMEs\* in clinical development to deliver breakthrough solutions

## Strong diverse pipeline with important read-outs in 2017



\* NME: New Molecular Entity

1 POC: Proof of concept

2 *bimekizumab*: psoriasis (Q3 2017), psoriatic arthritis and ankylosing spondylitis (Q2 2018)

● neurology  
● immunology



# Current vacancies

- **Research Associate/Scientist, Cellular Immunology**
- **Research Scientist, Characterisation**
- **Research Scientist, Mass Spectrometry/Biophysics**
- **Research Scientist – In Vivo Immunology**
- **Research/Senior Scientist, Biomarker**
- **Research/Senior Scientist, Cellular Immunology**

# Current vacancies

- **Senior/Principal Research Scientist - SPR**
- **Senior/Principal Scientist, Cell Pharmacology**
- **Principal Scientist, Discovery Analytics**
- **Principal/Senior Principal Scientist, Biomarker**
- **Principal/Senior Principal Scientist, Medicinal Chemistry**
- **Principal/Senior Principal Scientist, Protein Sciences**
- **Bioanalytical Scientific Manager**
- **Quantitative System Pharmacology**

# Questions?

# UCB

Inspired by **patients.**  
Driven by **science.**

Dale Starkie and Amy Sawtell  
Research Scientists, UCB

[ucb.com/careers](https://ucb.com/careers)



**Carolyn**, living with  
epilepsy and axial  
spondyloarthritis